EM2S

EM2S is a South Korean biotechnology company specializing in the development of next-generation cell therapies using its proprietary Engineered Macrophage-Mediated System (EM2S). The company focuses on leveraging macrophages as versatile therapeutic vehicles that can infiltrate solid tumors and modulate the immune microenvironment. By engineering these cells to deliver specific payloads or express therapeutic proteins, EM2S aims to overcome the limitations of current immunotherapies in treating hard-to-reach cancers and inflammatory conditions. Their technology platform enables the polarization of macrophages from a pro-tumor M2 state to an anti-tumor M1 state, enhancing the body's natural defense mechanisms. EM2S is currently advancing a pipeline of candidates targeting various solid malignancies and immune-related disorders.